Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy

Blood

Volumn 126, Issue 2, 2015, Pages 222-232

  Cho, Byung Sik ^a,b   Zeng, Zhihong ^a   Mu, Hong ^a   Wang, Zhiqiang ^a   Konoplev, Sergej ^a   McQueen, Teresa ^a   Protopopova, Marina ^a   Cortes, Jorge ^a   Marszalek, Joseph R ^a   Peng, Sheng Bin ^c   Ma, Wencai ^a   Davis, R Eric ^a   Thornton, Donald E ^c   Andreeff, Michael ^a   Konopleva, Marina ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b The Catholic University of Korea   (South Korea)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEUKEMIC AGENT; BETA CATENIN; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; CYTARABINE; DOXORUBICIN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; LY 2510924; PROTEIN KINASE B; STROMAL CELL DERIVED FACTOR 1ALPHA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CHEMOKINE RECEPTOR CXCR4; CYCLOPEPTIDE; LY2510924;

ACUTE MYELOBLASTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTILEUKEMIA ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CELL COUNT; CELL DEATH; CELL DIFFERENTIATION; CELL PROLIFERATION; CHEMOTAXIS; CONTROLLED STUDY; CRYPT CELL; DRUG EFFICACY; ENZYME PHOSPHORYLATION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL; MESENCHYMAL STROMA CELL; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT DURATION; TUMOR VOLUME; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; LEUKEMIA, MYELOID, ACUTE; NONOBESE DIABETIC MOUSE; PATHOLOGY; SCID MOUSE; TRANSGENIC MOUSE; TUMOR CELL CULTURE; U937 CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA, MYELOID, ACUTE; MICE; MICE, INBRED NOD; MICE, SCID; MICE, TRANSGENIC; PEPTIDES, CYCLIC; RECEPTORS, CXCR4; TUMOR CELLS, CULTURED; U937 CELLS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84937840502     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-02-628677     Document Type: Article

References (38)

1. Uy GL, Rettig MP, Motabi IH, et al. A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. Blood. 2012;119(17): 3917-3924.
2. Burger JA, Peled A. CXCR4 antagonists: Targeting the microenvironment in leukemia and other cancers. Leukemia. 2009;23(1):43-52.
3. Rombouts EJ, Pavic B, Löwenberg B, Ploemacher RE. Relation between CXCR-4 expression, Flt3 mutations, and unfavorable prognosis of adult acute myeloid leukemia. Blood. 2004;104(2):550-557.
4. Konoplev S, Rassidakis GZ, Estey E, et al. Overexpression of CXCR4 predicts adverse overall and event-free survival in patients with unmutated FLT3 acute myeloid leukemia with normal karyotype. Cancer. 2007;109(6): 1152-1156.
5. Nervi B, Ramirez P, Rettig MP, et al. Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. Blood. 2009;113(24): 6206-6214.
6. Zeng Z, Shi YX, Samudio IJ, et al. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood. 2009;113(24): 6215-6224.
7. Hendrix CW, Flexner C, MacFarland RT, et al. Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrob Agents Chemother. 2000;44(6):1667-1673.
8. Smith MC, Luker KE, Garbow JR, et al. CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res. 2004;64(23): 8604-8612.
9. Huang EH, Singh B, Cristofanilli M, et al. A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer. J Surg Res. 2009;155(2):231-236.
10. Hassan S, Buchanan M, Jahan K, et al. CXCR4 peptide antagonist inhibits primary breast tumor growth, metastasis and enhances the efficacy of anti-VEGF treatment or docetaxel in a transgenic mouse model. Int J Cancer. 2011;129(1):225-232.
11. Rubin JB, Kung AL, Klein RS, et al. A smallmolecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc Natl Acad Sci USA. 2003;100(23):13513-13518.
12. De Falco V, Guarino V, Avilla E, et al. Biological role and potential therapeutic targeting of the chemokine receptor CXCR4 in undifferentiated thyroid cancer. Cancer Res. 2007;67(24): 11821-11829.
13. Porvasnik S, Sakamoto N, Kusmartsev S, et al. Effects of CXCR4 antagonist CTCE-9908 on prostate tumor growth. Prostate. 2009;69(13): 1460-1469.
14. Schrader AJ, Lechner O, Templin M, et al. CXCR4/CXCL12 expression and signalling in kidney cancer. Br J Cancer. 2002;86(8): 1250-1256.
15. Drenckhan A, Kurschat N, Dohrmann T, et al. Effective inhibition of metastases and primary tumor growth with CTCE-9908 in esophageal cancer. J Surg Res. 2013;182(2):250-256.
16. Mo W, Chen J, Patel A, et al. CXCR4/CXCL12 mediate autocrine cell-cycle progression in NF1-associated malignant peripheral nerve sheath tumors. Cell. 2013;152(5):1077-1090.
17. Peng SB, Zhang X, Paul D, et al. Identification of LY2510924, a novel cyclic peptide CXCR4 antagonist that exhibits antitumor activities in solid tumor and breast cancer metastatic models. Mol Cancer Ther. 2015;14(2):480-490.
18. Galsky MD, Vogelzang NJ, Conkling P, et al. A phase I trial of LY2510924, a CXCR4 peptide antagonist, in patients with advanced cancer. Clin Cancer Res. 2014;20(13):3581-3588.
19. Chen Y, Jacamo R, Konopleva M, Garzon R, Croce C, Andreeff M. CXCR4 downregulation of let-7a drives chemoresistance in acute myeloid leukemia. J Clin Invest. 2013;123(6):2395-2407.
20. Battula VL, Chen Y, Cabreira MG, et al. Connective tissue growth factor regulates adipocyte differentiation of mesenchymal stromal cells and facilitates leukemia bone marrow engraftment. Blood. 2013;122(3):357-366.
21. Sison EA, McIntyre E, Magoon D, Brown P. Dynamic chemotherapy-induced upregulation of CXCR4 expression: A mechanism of therapeutic resistance in pediatric AML. Mol Cancer Res. 2013;11(9):1004-1016.
22. Kutok JL, Yang X, Folkerth R, Adra CN. Characterization of the expression of HTm4 (MS4A3), a cell cycle regulator, in human peripheral blood cells and normal and malignant tissues. J Cell Mol Med. 2011;15(1):86-93.
23. Jaatinen T, Hemmoranta H, Hautaniemi S, et al. Global gene expression profile of human cord blood-derived CD1331 cells. Stem Cells. 2006; 24(3):631-641.
24. Martens JH, Brinkman AB, Simmer F, et al. PMLRARalpha/RXR Alters the Epigenetic Landscape in Acute Promyelocytic Leukemia. Cancer Cell. 2010;17(2):173-185.
25. Whitman SP, Ruppert AS, Radmacher MD, et al. FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct geneexpression signature among younger adults with De novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications. Blood. 2008;111(3):1552-1559.
26. Fevr T, Robine S, Louvard D, Huelsken J. Wnt/beta-catenin is essential for intestinal homeostasis and maintenance of intestinal stem cells. Mol Cell Biol. 2007;27(21):7551-7559.
27. Zhang Y, Patel S, Abdelouahab H, et al. CXCR4 inhibitors selectively eliminate CXCR4-expressing human acute myeloid leukemia cells in NOG mouse model. Cell Death Dis. 2012;3:e396.
28. Peled A, Tavor S. Role of CXCR4 in the pathogenesis of acute myeloid leukemia. Theranostics. 2013;3(1):34-39.
29. Abdel-Wahab O, Levine RL. Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia. Blood. 2013;121(18):3563-3572.
30. Tavor S, Eisenbach M, Jacob-Hirsch J, et al. The CXCR4 antagonist AMD3100 impairs survival of human AML cells and induces their differentiation. Leukemia. 2008;22(12):2151-2158.
31. Datta SR, Brunet A, Greenberg ME. Cellular survival: A play in three Akts. Genes Dev. 1999;13(22):2905-2927.
32. Nebreda AR, Gavin AC. Perspectives: Signal transduction. Cell survival demands some Rsk. Science. 1999;286(5443):1309-1310.
33. Tilton B, Ho L, Oberlin E, et al. Signal transduction by CXC chemokine receptor 4. Stromal cellderived factor 1 stimulates prolonged protein kinase B and extracellular signal-regulated kinase 2 activation in T lymphocytes. J Exp Med. 2000; 192(3):313-324.
34. Tabe Y, Jin L, Tsutsumi-Ishii Y, et al. Activation of integrin-linked kinase is a critical prosurvival pathway induced in leukemic cells by bone marrow-derived stromal cells. Cancer Res. 2007; 67(2):684-694.
35. Kuhne MR, Mulvey T, Belanger B, et al. BMS-936564/MDX-1338: A fully human anti-CXCR4 antibody induces apoptosis in vitro and shows antitumor activity in vivo in hematologic malignancies. Clin Cancer Res. 2013;19(2): 357-366.
36. Tabe Y, Konopleva M. Advances in understanding the leukaemia microenvironment. Br J Haematol. 2014;164(6):767-778.
37. Becker SP, Foran MJ, Altman KJ, et al. Targeting the CXCR4 Pathway: Safety, Tolerability and Clinical Activity of Ulocuplumab (BMS-936564), an Anti-CXCR4 Antibody, in Relapsed/Refractory Acute Myeloid Leukemia [abstract]. Blood. 2014; 124:(21). Abstract 386.
38. Borthakur G, Nagler A, Ofran Y, et al. BL-8040, a Peptidic CXCR4 Antagonist, Induces Leukemia Cell Death and Specific Leukemia Cell Mobilization in Relapsed/Refractory Acute Myeloid Leukemia Patients in an Ongoing Phase IIa Clinical Trial [abstract]. Blood. 2014; 124:(21). Abstract 950.